Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong
· Delayed Price · Currency is HKD 22.65
+0.50 (2.26%)
Jun 27, 2025, 3:59 PM HKT
Biocytogen Pharmaceuticals (Beijing) Employees
Biocytogen Pharmaceuticals (Beijing) had 1,117 employees as of December 31, 2024. The number of employees increased by 51 or 4.78% compared to the previous year.
Employees
1,117
Change (1Y)
51
Growth (1Y)
4.78%
Revenue / Employee
934.08K HKD
Profits / Employee
31.96K HKD
Market Cap
9.05B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,117 | 51 | 4.78% |
| Dec 31, 2023 | 1,066 | -282 | -20.92% |
| Dec 31, 2022 | 1,348 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| JD Health International | 3,564 |
| Innovent Biologics | 5,659 |
| WuXi Biologics | 12,575 |
| Sino Biopharmaceutical | 24,379 |
| CSPC Pharmaceutical Group | 21,400 |
| Akeso | 3,035 |
Biocytogen Pharmaceuticals (Beijing) News
- 12 days ago - Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing - Financial Post
- 24 days ago - Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform - Business Upturn
- 24 days ago - Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009) - Financial Post
- 6 months ago - Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors - Financial Post